Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic
chemotherapy regimens have not produced optimal long-term outcomes, and many …

Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic
chemotherapy have plateaued. Recent technological advances allows for a comprehensive …

Urothelial cell carcinoma (UCC) is a common cancer, with over 80,000 estimated new cases
in the United States of America (USA) in 2024 (1). There continues to be a greater than 3: 1 …

Conclusion The development of novel therapies targeting the immune and molecular
pathways of advanced urothelial carcinoma is promising for the improvement of outcomes in …

First-line platinum-based chemotherapy combinations are considered standard-of-care in
locally advanced and metastatic urothelial cancer. However, long-term outcomes, including …

Simple Summary Urothelial carcinoma is a malignancy of the cells lining the genitourinary
tract but it most commonly occurs in the bladder. Once urothelial carcinoma has spread …

Metastatic urothelial cancer (UC) is associated with poor prognosis. In the first-line setting,
platinum-based chemotherapy is the standard of care but resistance rapidly occurs. With no …

Urothelial carcinoma represents one of the most prevalent types of cancer worldwide, and its
incidence is expected to grow. Although the treatment of the advanced disease was based …

The use of immunotherapy has revolutionized the management of patients with locally
advanced, unresectable, and metastatic urothelial carcinoma (UC); however, platinum …

Despite recent advances in the identification of genomic alterations that lead to urothelial
oncogenesis in vitro, patients with advanced urothelial carcinomas continue to have poor …